Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals' stockholders approved the 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan (ESPP) at the Annual Meeting on June 10, 2026. The 2026 Equity Incentive Plan reserves 7,200,000 shares of common stock, along with shares recycled from the previous 2015 plan, to incentivize employees, directors, and consultants. The 2026 ESPP, a successor to the 2015 ESPP, aims to secure and retain employees by allowing them to purchase company common stock. Additionally, stockholders elected directors, approved executive compensation on an advisory basis, and ratified the selection of the independent auditor.

Syndax Pharmaceuticals announced it granted inducement awards to four new employees on June 1, 2026. These awards allow the purchase of up to 66,700 shares of common stock under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting monthly over the subsequent 36 months, subject to continued employment.

Syndax Pharmaceuticals Inc. announced a private placement of $250.0 million in aggregate principal amount of 2.25% Convertible Senior Notes due 2031. The sale is expected to close on June 10, 2026, with estimated net proceeds of $243 million intended for general corporate purposes. The notes will mature in June 2031 and are convertible under certain conditions, with an initial conversion price representing a 35% premium over the recent stock price. The company may redeem the notes starting in June 2029, and noteholders have repurchase rights upon a fundamental change.

Syndax Pharmaceuticals has entered into privately negotiated agreements for the issuance of $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031. The private placement is expected to close on June 10, 2026, yielding approximately $243 million in net proceeds. Syndax plans to utilize these funds for general corporate purposes, including working capital, research and development, commercialization, and business development expenditures. The notes will mature on June 15, 2031, and have an initial conversion price of $24.76 per share, representing a 35% premium over the last reported sale price.

Syndax Pharmaceuticals presented new Revuforj® (revumenib) data at the ASCO 2026 Annual Meeting, highlighting favorable outcomes in a pooled analysis of 24 acute leukemia patients who resumed revumenib post-transplant. The data showed a 2-year overall survival rate of 90%, significantly higher than the historical benchmark of 51%. Additionally, pharmacokinetic data indicated that revumenib can be administered with gastric acid reducing agents without compromising efficacy. Syndax plans further research in the post-transplant setting, including the MenTain study, a randomized, placebo-controlled trial.

Syndax Pharmaceuticals announced the acceptance of four Revuforj® (revumenib) abstracts for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. An oral presentation will highlight favorable outcomes observed among 21 adults and children with acute leukemia who received revumenib post-transplant, including overall survival and relapse rates. Additionally, data on revumenib's pharmacokinetic profile, demonstrating its compatibility with gastric acid reducing agents and low-fat meals, will be presented. The company will also showcase the design of ongoing pivotal Phase 3 trials for revumenib in newly diagnosed acute leukemia.

Syndax Pharmaceuticals announced that its Chief Executive Officer, Michael A. Metzger, along with other members of the management team, will participate in three upcoming investor conferences. These include the TD Cowen 7th Annual Oncology Innovation Summit, the Jefferies Global Healthcare Conference, and the Goldman Sachs 47th Annual Global Healthcare Conference. Live webcasts and replays of the fireside chats will be accessible through the company's investor relations website.

Syndax Pharmaceuticals announced the release of 12 Revuforj® (revumenib) abstracts for the European Hematology Association (EHA) 2026 Congress. The data highlights strong activity across various acute leukemia subtypes (KMT2Ar, NPM1m, NUP98r), compelling real-world outcomes, and favorable tolerability in both monotherapy and combination use. Encouraging results were also observed in the post-transplant setting and with frontline/relapsed/refractory combinations, bolstering confidence in Revuforj's potential to transform AML treatment.

Syndax Pharmaceuticals announced it granted inducement awards to eight new employees on May 1, 2026. These awards allow the purchase of up to 162,100 shares of common stock under the Company's 2023 Inducement Plan. The stock options will vest over four years, with an initial 25% vesting after one year, followed by monthly vesting over the subsequent 36 months, contingent on continued employment.

Syndax Pharmaceuticals, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 10, 2026. Stockholders will vote on the election of two Class I directors, an advisory resolution on executive compensation, and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm. Additionally, stockholders will consider the approval of the 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan.